BMJ6d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ12d
Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis
Objective We aimed to understand the role of the transcriptional co-factor Yes-associated protein (Yap) in the molecular pathway underpinning the pathogenic transformation of synovial fibroblasts (SF) ...
BMJ7d
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
2 Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands 3 Rheumatology Department, Maastricht University Medical Center, Maastricht, The Netherlands Background The ...
BMJ11d
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
Objectives To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor. Methods ...
BMJ8d
Medications associated with fracture risk in patients with rheumatoid arthritis
Objective To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications ...
BMJ9d
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Objectives Various hypotheses exist for the explanation of placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis with IR to methotrexate (MTX). We ...
BMJ9d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ5d
Oral steroid in the treatment of carpal tunnel syndrome
Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China A range of options are available for the ...
BMJ4d
How the type of risk reduction influences required sample sizes in randomised clinical trials
Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands Correspondence to: Professor D van der Heijde Department of Internal Medicine, Division ...
BMJ4d
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...
BMJ13d
Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis
5 CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Faculté de Médecine, University of Paris City, Paris, France Objectives Alterations in tryptophan (Trp) metabolism have ...
BMJ12d
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Objective To develop and validate a diagnostic score that aids in identifying macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (sJIA). Methods The clinical ...